Enteralia Bioscience
Enteralia develops a novel gluten‑degrading enzyme (E40) to treat celiac disease and non‑celiac gluten sensitivity.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Enteralia develops a novel gluten‑degrading enzyme (E40) to treat celiac disease and non‑celiac gluten sensitivity.
Gastrointestinal DisordersCeliac DiseaseNon‑Celiac Gluten Sensitivity
Technology Platform
Proprietary enzymatic glutenase (E40) that degrades immunogenic gluten peptides to halt the initial pathogenic step in gluten‑related disorders.
Opportunities
A large, unmet patient population for gluten‑related disorders creates significant commercial potential for an effective enzymatic therapy.
Risk Factors
Regulatory approval, clinical efficacy, and manufacturing scalability are key hurdles for advancing the enzyme to market.
Competitive Landscape
Enteralia competes with other glutenase developers (e.g., AN‑PEP, ALV‑001) but differentiates through its proprietary enzyme design and focus on both celiac disease and non‑celiac gluten sensitivity.